TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed

Rhea-AI Summary

TriSalus Life Sciences (Nasdaq: TLSI) has announced a $10 million drawdown from its existing $50 million credit agreement with OrbiMed, a healthcare investment firm. This drawdown was triggered by achieving a product revenue-based milestone of $30 million for the trailing 12-months ending January 31, 2025. With this latest tranche, TriSalus has now accessed a total of $35 million from the credit facility provided by OrbiMed.

Positive

• Successfully achieved $30 million revenue milestone triggering loan availability
• Secured additional $10 million in financing to support operations
• Demonstrated ability to meet credit facility requirements

Negative

• Increased debt obligations by $10 million
• Company continues to rely on debt financing for operations

Insights

Financial Analyst

This financing development reveals several positive indicators about TriSalus's business trajectory. The achievement of $30 million in trailing 12-month product revenue demonstrates significant commercial traction for their medical device portfolio, particularly in the oncology space. The milestone-based structure of the OrbiMed facility is particularly noteworthy, as it provides validation from a sophisticated healthcare investor while minimizing dilution for existing shareholders.

The decision to draw down this $10 million tranche suggests careful capital management, with the company maintaining $15 million in additional facility capacity for future needs. OrbiMed's continued support through this facility provides strategic flexibility for TriSalus to advance both its device business and immunotherapy pipeline. The debt financing structure is particularly advantageous in the current high-interest-rate environment, where equity financing might be more costly to shareholders.

The revenue milestone achievement is especially meaningful for a company with a market cap of approximately $160 million, as it represents a healthy revenue-to-market-cap ratio and suggests strong commercial execution. This additional capital infusion strengthens TriSalus's position to continue investing in its dual-platform strategy of delivery technology and immunotherapy development.

DENVER--(BUSINESS WIRE)-- TriSalus Life Sciences® Inc. (Nasdaq: TLSI), a biomedical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies and its investigational immunotherapy, today announced that it has requested a drawdown of $10 million under its previously announced $50 million credit agreement with OrbiMed, a healthcare investment firm.

Pursuant to the to the Agreement, OrbiMed agreed to provide a term loan facility in an aggregate principal amount of $50 million. The $10 million drawdown became available to TriSalus upon achievement of product revenue-based milestone of $30 million for the trailing 12-months ending on January 31, 2025. With the closing of the $10 million tranche, the company has drawn a total of $35 million under the credit agreement with OrbiMed.

About TriSalus Life Sciences

TriSalus Life Sciences® is an oncology focused medical technology business providing disruptive drug delivery technology with the goal of improving therapeutic delivery to solid tumors. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy. The Company’s two FDA-cleared devices use its proprietary Pressure-Enabled Drug Delivery™ (PEDD™) approach to deliver a range of therapeutics: the TriNav® Infusion System for hepatic arterial infusion of liver tumors as well as other solid tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD is a novel delivery approach designed to address the anatomic limitations of infusion into solid tumors. The PEDD approach modulates pressure and flow in a manner that delivers more therapeutic to the tumor and is designed to limit delivery to normal tissue, creating the potential to improve patient outcomes. Nelitolimod, the Company’s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment created by many tumors and which can make current immunotherapies ineffective in the liver and pancreas. Patient data generated during Pressure-Enabled Regional Immuno-Oncology™ (PERIO) clinical trials support the hypothesis that nelitolimod delivered via PEDD may have favorable immune effects within the liver and systemically. The target for nelitolimod, TLR9, is expressed across cancer types and the mechanical barriers addressed by PEDD are commonly present as well. Nelitolimod delivered by PEDD will be studied across several indications in an effort to address immune dysfunction and overcome drug delivery barriers in the liver and pancreas.

In partnership with leading cancer centers across the country – and by leveraging deep immuno-oncology expertise and inventive technology development – TriSalus is committed to advancing innovation that improves outcomes for patients. Learn more at trisaluslifesci.com and follow us on X (formerly Twitter) and LinkedIn.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this report, including statements regarding the Company’s financial results for the three months ended December 31, 2024 and the full year ended December 31, 2024, the Company’s belief as to the factors causing the financial results, the Company’s expectation that it will have sufficient liquidity to fund operations through 2025, the Company’s expectations for sales growth, positive full year EBITDA and positive cash flow during 2025, the Company’s ability to access the additional $10 million tranche under its OrbiMed debt facility, are all forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “expect,” “may,” “potential,” “should,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology.

The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to, the risk that our reported financial results will differ from the estimates provided in this press release, the risk that the Company will not be able to achieve its expected sales growth, EBITDA and cash flow during 2025, the risk that the Company will not be able to obtain additional liquidity, the risk that the Company will not continue as a going concern, and other risk factors described in the Company’s filings with the Securities and Exchange Commission, including the section titled “Risk Factors”. See the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 14, 2024 and other filings made with the SEC for a discussion of important factors that may cause the Company’s actual results to differ materially from those expressed or implied by the Company’s forward looking statements. Moreover, the Company operates in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for the Company’s management to predict all risk factors nor can the Company assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements.

In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Furthermore, if the Company’s forward-looking statements prove to be inaccurate, the inaccuracy may be material. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250203362960/en/

For Media Inquiries:

Jeremy Feffer, Managing Director

LifeSci Advisors

917.749.1494

jfeffer@lifesciadvisors.com

For Investor Inquiries:

James Young

Chief Financial Officer

847.337.0655

james.young@trisaluslifesci.com

Source: TriSalus Life Sciences

FAQ

How much has TriSalus Life Sciences (TLSI) drawn from its OrbiMed credit facility as of 2024?

TriSalus has drawn a total of $35 million from its $50 million credit facility with OrbiMed, following the latest $10 million drawdown.

What revenue milestone did TLSI achieve to unlock the $10 million credit tranche?

TLSI achieved a product revenue-based milestone of $30 million for the trailing 12-months ending January 31, 2025, which triggered the availability of the $10 million tranche.

How much remains available in TLSI's credit facility with OrbiMed?

Following the $10 million drawdown, $15 million remains available from the original $50 million credit facility.

What is the total value of TLSI's credit agreement with OrbiMed?

The total credit agreement between TriSalus Life Sciences and OrbiMed is valued at $50 million.